TranS1 reported total revenue of $4 million during the fourth quarter of 2011, a 32 percent decrease from the same period in 2010.
The drop was driven by a 73.9 percent decrease in domestic sales to $3.7 million during the fourth quarter of 2011. However, the company recently received approval for its new Category I CPT code for the L5/S1 spinal fusion using the AxiaLIF implant when performing a pre-sacral interbody fusion. The CPT Editorial Panel also voted to establish a new Category III CPT code as an add-on for surgeons performing L4/L5 spinal fusions. The new codes will be effective Jan. 1, 2013.
During the fourth quarter, the company reported 310 TranS1 procedures performed globally. For the full year, TranS1 reported $19 million in revenue, a $7 million decrease from 2010.
More Articles on Orthopedic Devices:
44 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in February
Zimmer to Move Some Operations From Indiana to Tennessee
Globus Medical Settles FDA Administrative Complaint
During the fourth quarter, the company reported 310 TranS1 procedures performed globally. For the full year, TranS1 reported $19 million in revenue, a $7 million decrease from 2010.
More Articles on Orthopedic Devices:
44 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in February
Zimmer to Move Some Operations From Indiana to Tennessee
Globus Medical Settles FDA Administrative Complaint